News Sentiment

EQ sentiment intelligence

Equillium Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.91 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+0.0% over one week, +3.6% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Piper Sandler Initiates Equillium(EQ.US) With Buy Rating, Announces Target Price $20

Market Reaction

Balanced read

55/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction 0.0% Price digesting
Trend fit Trend active 3.6% over four weeks
Fair value 147.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 32
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 8
Market source 6
Stock Titan 5
Moomoo 4
TradingKey 4
GlobeNewswire 4
www.marketscreener.com 3
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 14
Analyst action 6
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
Moomoo Direct company coverage

Piper Sandler Initiates Equillium(EQ.US) With Buy Rating, Announces Target Price $20

Piper Sandler has initiated coverage on Equillium (EQ.US) with a Buy rating. The financial firm has set a target price of $20 for the company's stock. This indicates a positive outlook from Piper Sandler regarding Equillium's future performance.

Tone
Positive 77/100
Event
Analyst action
Published
14 Jul 2026 19:39
Source
Moomoo
Investing.com Direct company coverage

Piper Sandler initiates Equillium stock with overweight rating

Piper Sandler has initiated coverage on Equillium Inc. (NASDAQ:EQ) with an overweight rating and a $20.00 price target, citing the company's lead asset EQ504 for ulcerative colitis. The firm highlights strong preclinical data for EQ504, a robust balance sheet, and significant ret

Tone
Positive 82/100
Event
Analyst action
Published
13 Jul 2026 09:10
Source
Investing.com
marketscreener.com Direct company coverage

Piper Sandler Initiates Coverage on Equillium With Overweight Rating, $20 Price Target

Piper Sandler has initiated coverage on Equillium (NasdaqCM:EQ) with an Overweight rating and set a $20 price target. This announcement was made on July 13, 2026, at 08:15 am EDT. Equillium is a clinical-stage biotechnology company focused on developing novel therapeutics for sev

Tone
Positive 70/100
Event
Analyst action
Published
13 Jul 2026 08:15
Source
marketscreener.com
TradingView Direct company coverage

ETFs Investing in Equillium, Inc. Stocks

This article lists Exchange Traded Funds (ETFs) that invest in Equillium, Inc. stocks, providing financial data for each fund including market value, weight, issuer, expense ratio, and performance. Two ETFs, iShares Microcap ETF (IWC) and Invesco NASDAQ Future Gen 200 ETF (QQQS),

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 03:09
Source
TradingView
Quartr Direct company coverage

Equillium (EQ) Cantor Global Healthcare Conference 2025 Summary

Equillium recently completed a $50 million financing round, with $30 million upfront, to advance its novel AhR modulator program, EQ504, targeting severe autoimmune and inflammatory diseases, particularly ulcerative colitis. Clinical development for EQ504 is expected to commence

Tone
Positive 72/100
Event
Market update
Published
02 Jul 2026 15:10
Source
Quartr
www.marketscreener.com Direct company coverage

Equillium, Inc.(NasdaqCM: EQ) added to Russell 3000E Index

Equillium, Inc. (NasdaqCM: EQ), a clinical-stage biotechnology company, has been added to the Russell 3000E Index. The company is focused on developing novel therapeutics for severe autoimmune and inflammatory disorders, with a pipeline including immunomodulatory assets like EQ30

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 00:09
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Equillium, Inc.(NasdaqCM: EQ) added to Russell Microcap Index

Equillium, Inc. (NasdaqCM: EQ), a clinical-stage biotechnology company, has been added to the Russell Microcap Index, as well as the Russell 3000E Index and Russell 3000E Growth Benchmark. This inclusion highlights the company's growing market presence and visibility within the f

Tone
Positive 75/100
Event
Market update
Published
29 Jun 2026 11:10
Source
www.marketscreener.com
TradingView Direct company coverage

Price to sales forward of Equillium, Inc. – NASDAQ:EQ

This article provides financial data for Equillium, Inc. (NASDAQ: EQ), specifically focusing on its price-to-sales forward ratio. It appears to be a stub or a data point from a financial platform like TradingView, indicating that the specific period, value, and change information

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 11:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Equillium, Inc. – NASDAQ:EQ

This article focuses on the enterprise value to EBIT forward ratio for Equillium, Inc. (NASDAQ: EQ). It is a financial data point presented within the context of TradingView's platform, offering an overview of the company's financial metrics. The content is primarily a data displ

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 03:39
Source
TradingView
TradingView Direct company coverage

Price to book forward of Equillium, Inc. – NASDAQ:EQ

The article focuses on the "Price to book forward" metric for Equillium, Inc. (NASDAQ: EQ) as presented on the TradingView platform. It indicates that the current market for EQ is closed with no trades. The content primarily lists financial and market data sources and disclaimers

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 00:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Equillium, Inc. – NASDAQ:EQ

This article displays financial data for Equillium, Inc. (NASDAQ: EQ) related to its enterprise value to revenue forward metric. The content is presented within the TradingView platform, noting that markets are closed and showing no trades at the time of viewing. It appears to be

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 21:33
Source
TradingView
TradingView Direct company coverage

Equillium, Inc. Actuals & Estimates (NASDAQ:EQ)

This article provides financial actuals and estimates for Equillium, Inc. (EQ) traded on NASDAQ. It covers stock performance, analyst forecasts, historical prices, market capitalization, earnings reports, and other key financial metrics. The company's stock has seen a significant

Tone
Positive 66/100
Event
Earnings
Published
25 Jun 2026 13:10
Source
TradingView
TradingKey Direct company coverage

Equillium Inc (EQ) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Equillium Inc (EQ), detailing its price momentum, support and resistance levels, and key technical indicators. As of June 25, 2026, EQ has a price momentum score of 9.04, ranking high in its industry. The analysis suggests the stock i

Tone
Positive 65/100
Event
Market update
Published
24 Jun 2026 21:39
Source
TradingKey
Simply Wall Street Direct company coverage

23% Of This Equillium Insider's Holdings Were Sold

Insiders at Equillium (NASDAQ:EQ) have been net sellers over the last year, with Chief Scientific Officer & President Stephen Connelly selling US$724k worth of shares at US$3.16 per share. While the sale occurred around the current share price of US$2.99, indicating it's not a ma

Tone
Negative 40/100
Event
Market update
Published
18 Jun 2026 11:09
Source
Simply Wall Street
TradingKey Direct company coverage

Equillium Inc (EQ) Earnings Forecast: Future EPS & Revenue Growth Estimates

Equillium Inc (EQ) has an earnings forecast score of 9.25, ranking 7th in the Biotechnology & Medical Research industry. Analysts have an average price target of $2.50 for EQ, with most recommending a "STRONG BUY" rating. The company's previous quarter EPS was -$0.04, beating the

Tone
Positive 73/100
Event
Earnings
Published
17 Jun 2026 22:09
Source
TradingKey
TradingKey Direct company coverage

Equillium Inc (EQ) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides a financial overview of Equillium Inc (EQ), focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends in the past five years and has no recorded stock splits. The report includes current stock performan

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 20:09
Source
TradingKey
TradingKey Direct company coverage

Equillium Inc (EQ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for Equillium Inc (EQ) by business segment and region. However, it explicitly states that the relevant data for such a breakdown has not yet been disclosed by the company. The page primarily serves as an overvie

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 20:09
Source
TradingKey
Insider Monkey Direct company coverage

Analysts Grow More Confident In Equillium’s (EQ) Lead Asset EQ504

Equillium, Inc. (EQ) has seen increasing analyst confidence in its lead asset, EQ504, for ulcerative colitis. Leerink upgraded its rating to "Outperform" with a $6 price target, citing strong clinical and mechanistic validation and forecasting $1.5 billion in worldwide sales by 2

Tone
Positive 81/100
Event
Analyst action
Published
10 Jun 2026 13:45
Source
Insider Monkey
Stock Titan Direct company coverage

Equillium (NASDAQ: EQ) Form 144: insider resale activity, 200,000-share sale noted

Equillium, Inc. filed a Form 144 indicating proposed insider sales. The filing notes 30,975 shares "to be sold" and reported a past sale of 200,000 shares by Stephen Connelly on 06/04/2026, with Jefferies LLC listed as the broker. These shares are identified as "Founders shares a

Tone
Neutral 50/100
Event
Market update
Published
06 Jun 2026 01:08
Source
Stock Titan
GuruFocus Direct company coverage

Insider Sell: Stephen Connelly Sells 230,975 Shares of Equillium Inc (EQ)

Stephen Connelly, President and Chief Scientific Officer of Equillium Inc's subsidiary, sold 230,975 shares of Equillium Inc (EQ) on June 5, 2026. Following this transaction, Connelly now owns 762,025 shares. Equillium Inc, a biotechnology company, has seen 12 insider sells and 0

Tone
Negative 30/100
Event
Market update
Published
05 Jun 2026 22:08
Source
GuruFocus
www.marketscreener.com Direct company coverage

Equillium Insider Sold Shares Worth $723,830, According to a Recent SEC Filing

An insider at Equillium (EQ) sold shares worth $723,830, as revealed in a recent SEC filing. This transaction occurred on June 5, 2026, following another insider share sale worth $267,209 on June 1, 2026. Equillium is a clinical-stage biotechnology company focused on developing t

Tone
Negative 38/100
Event
Market update
Published
05 Jun 2026 21:09
Source
www.marketscreener.com
Investing.com Direct company coverage

Equillium COO Christine Zedelmayer sells $42,736 in stock

Equillium's COO, Christine Zedelmayer, sold 14,584 shares of company stock for approximately $42,736, shortly after acquiring them through employee stock options. This sale was made under a Rule 10b5-1 trading plan. The timing coincides with significant stock performance gains an

Tone
Positive 67/100
Event
Market update
Published
05 Jun 2026 21:08
Source
Investing.com
Stock Titan Direct company coverage

Equillium (EQ) COO sells 14,584 shares after exercising stock options

Equillium, Inc. (EQ) Senior Vice President and COO Christine Zedelmayer exercised stock options to acquire 14,584 shares and subsequently sold the same number of shares on the open market. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. After the sale

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 21:08
Source
Stock Titan
Stock Titan Direct company coverage

Equillium (NASDAQ: EQ) CSO Stephen Connelly sells 230,975 shares in open market

Equillium's President and CSO, Stephen Connelly, sold a total of 230,975 shares of the company's common stock in open-market transactions on June 4 and June 5, 2026. The sales were executed at weighted average prices of $3.1638 and $2.9401 per share, respectively. Following these

Tone
Negative 28/100
Event
Market update
Published
05 Jun 2026 21:08
Source
Stock Titan
Stock Titan Direct company coverage

[144] Equillium, Inc. SEC Filing

This SEC filing for Equillium, Inc. (EQ) is a Form 144, indicating a notice of proposed sale of securities under Rule 144. The filing details the sale of 200,000 common shares by a founder, acquired at incorporation, with an aggregate market value of $632,760.00 through Jefferies

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 21:38
Source
Stock Titan
Moomoo Direct company coverage

Equillium(EQ) Stock Options Chain | Quotes & News

This article provides the stock options chain for Equillium (EQ) and includes quotes and news related to the company. It serves as a resource for investors interested in EQ's options market.

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 17:11
Source
Moomoo
Moomoo Direct company coverage

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equillium, Inc. announced inducement grants of stock options and restricted stock units (RSUs) to three new non-executive employees. These grants were made outside of the company’s 2021 Equity Incentive Plan as an inducement material to their employment, in accordance with Nasdaq

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 12:40
Source
Moomoo